The atypical pneumonias: clinical diagnosis and importance  by Cunha, B.A.
REVIEW
The atypical pneumonias: clinical diagnosis and importance
B. A. Cunha
Infectious Disease Division, Winthrop-University Hospital, Mineola, New York and State University of
New York School of Medicine, Stony Brook, New York, USA
ABSTRACT
The most common atypical pneumonias are caused by three zoonotic pathogens, Chlamydia psittaci
(psittacosis), Francisella tularensis (tularemia), and Coxiella burnetii (Q fever), and three nonzoonotic
pathogens, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella. These atypical agents, unlike
the typical pathogens, often cause extrapulmonary manifestations. Atypical CAPs are systemic
infectious diseases with a pulmonary component and may be differentiated clinically from typical
CAPs by the pattern of extrapulmonary organ involvement which is characteristic for each atypical
CAP. Zoonotic pneumonias may be eliminated from diagnostic consideration with a negative contact
history. The commonest clinical problem is to differentiate legionnaire’s disease from typical CAP as
well as from C. pneumoniae or M. pneumonia infection. Legionella is the most important atypical pathogen
in terms of severity. It may be clinically differentiated from typical CAP and other atypical pathogens by
the use of a weighted point system of syndromic diagnosis based on the characteristic pattern of
extrapulmonary features. Because legionnaire’s disease often presents as severe CAP, a presumptive
diagnosis of Legionella should prompt speciﬁc testing and empirical anti-Legionella therapy such as the
Winthrop-University Hospital Infectious Disease Division’s weighted point score system. Most atypical
pathogens are difﬁcult or dangerous to isolate and a deﬁnitive laboratory diagnosis is usually based on
indirect, i.e., direct ﬂourescent antibody (DFA), indirect ﬂourescent antibody (IFA). Atypical CAP is
virtually always monomicrobial; increased IFA IgG tests indicate past exposure and not concurrent
infection. Anti-Legionella antibiotics include macrolides, doxycycline, rifampin, quinolones, and
telithromycin. The drugs with the highest level of anti-Legionella activity are quinolones and
telithromycin. Therapy is usually continued for 2 weeks if potent anti-Legionella drugs are used. In
adults,M. pneumoniae and C. pneumoniaemay exacerbate or cause asthma. The importance of the atypical
pneumonias is not related to their frequency (15% of CAPs), but to difﬁculties in their diagnosis, and
their nonresponsiveness to b-lactam therapy. Because of the potential role of C. pneumoniae in coronary
artery disease and multiple sclerosis (MS), and the role ofM. pneumoniae and C. pneumoniae in causing or
exacerbating asthma, atypical CAPs also have public health importance.
Keywords Atypical pneumonias, clinical diagnosis of legionnaire’s disease, community-acquired pneumonia,
doxycycline, legionnaire’s disease, Mycoplasma pneumonia, Chlamydia pneumonia, quinolones, review, telithro-
mycin , therapy of Legionella
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INTRODUCTION
The term ‘atypical pneumonia’ was ﬁrst applied to
viral community-aquired pneumonias (CAP) that
were clinically and radiologically distinct from
bacterial CAPs. Over the past decades, atypical
pneumonia has come to mean lower respiratory
tract infections due to speciﬁc respiratory patho-
gens, i.e., Chlamydia psittaci (psittacosis), Francisella
tularensis (tularemia), Coxiella burnetii (Q fever),
Chlamydia pneumoniae, Mycoplasma pneumoniae or
Legionella species [1–5]. The newly recognised
causes of CAP, i.e., severe acute respiratory
syndrome (SARS), hantavirus, and avian inﬂu-
enza, are not considered ‘atypical pneumonias’,
but should be regarded as viral CAPs [5,6].
Atypical CAPs represent approximately 15% of
all CAPs. While outbreaks due to atypical pneu-
monia pathogens occur in the community, most
cases of atypical CAP are sporadic. Atypical
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pulmonary pathogens causing pneumonia may
also cause outbreaks of nursing home-acquired
pneumonia (NHAP) or nosocomial pneumonia
(NP). Atypical pneumonia as a cause of NHAP or
NP is rare. Atypical pathogens are more common
than typical bacterial pathogens in mild or ambu-
latory CAP in adults. Legionella is an important
cause of severe CAP in hospitalised patients
[4,5,7–10].
The atypical pneumonias may be classiﬁed
clinically as those that are zoonotically transmit-
ted and those that are not. The zoonotic atypical
pneumonias include psittacosis, Q fever, and
tularaemia, and the nonzoonotic atypical pneu-
monias include Mycoplasma, Chlamydia pneumoni-
ae, and Legionella CAPs. Both the zoonotic and
nonzoonotic atypical pneumonias differ funda-
mentally from bacterial CAPs. However, the main
feature differentiating atypical from typical CAP
pathogens is the presence or absence of extrapul-
monary ﬁndings. All atypical pulmonary patho-
gens, both zoonotic and nonzoonotic, cause
systemic infectious disease with a pulmonary
component, i.e., pneumonia. Pneumonias caused
by Streptococcus pneumoniae, Haemophilus inﬂuen-
zae, or Moraxella catarrhalis are typical CAPs with
clinical and laboratory ﬁndings limited to the
lungs. Once this distinction is made in CAP with
extrapulmonary ﬁndings, the clinician can then
determine the characteristic pattern of organ
involvement and narrow down the diagnostic
possibilities [4–10].
Each atypical pulmonary pathogen has a pre-
dilection for certain extrapulmonary organ sys-
tems. It is the characteristic pattern of organ
involvement rather than individual clinical or
laboratory ﬁndings, that distinguishes the atypical
pneumonias from each other. The extrapulmonary
pattern of organ involvement of Legionella, for
example, is very different and distinct from
C. pneumoniae or Mycoplasma CAP, and provides
the basis for a presumptive clinical diagnosis. If
the distinctive patterns of extrapulmonary organ
involvement associated with each atypical patho-
gen are recognised, a presumptive clinical diag-
nosis is usually straightforward and accurate.
Presumptive clinical diagnosis is not deﬁnitive
but should prompt speciﬁc diagnostic testing to
conﬁrm or rule out speciﬁc pathogens [1–4,7–10].
In the literature, most studies have been unable
to clearly differentiate typical from atypical pneu-
monias. The main difﬁculty with such studies is
that they have compared individual clinical and
laboratory ﬁndings of atypical and typical path-
ogens. These studies correctly concluded that
there are few, if any, discernible differences in
isolated ﬁndings. Only rarely have studies used a
syndromic diagnosis, and only one has used a
weighted syndromic point system of diagnosis.
Using a weighted syndromic approach based on
the relative clinical speciﬁcity of characteristic
clinical ﬁndings, it is clear that with good sensi-
tivity and speciﬁcity, clinicians can not only
differentiate typical from atypical pneumonias,
but can accurately presumptively diagnose
legionnaire’s disease [11–14].
The importance of the atypical pneumonias is
not based on their clinical incidence per se, which
is important enough, but rather on other clinical
and public health aspects. The atypical pneumo-
nias require a different therapeutic approach
than that for typical CAPs [1,2,15]. Atypical
CAP pathogens, particularly M. pneumoniae and
C. pneumoniae constitute the majority of CAPs in
young adults in the ambulatory or outpatient
setting. The outpatient setting is the area where
atypical pathogens are quantitatively more
important than their typical CAP counterparts.
Atypical pathogens, particularly Legionella, also
are an important cause of severe CAP. Typical
bacterial pathogens have classically responded to
b-lactam antimicrobial therapy because they have
a cell wall amenable to b-lactam disruption. In
contrast, most of the atypical pathogens do not
have a bacterial cell wall and some are intracel-
lular, e.g., Legionella, and still others are paracel-
lular, e.g., M. pneumoniae [1,2,9,10].
Antimicrobials that inhibit or eradicate micro-
organisms by interfering with intracellular pro-
tein synthesis enzymes are effective against
atypical pathogens. Macrolides and tetracyclines
interfere with intracellular bacterial protein syn-
thesis. Quinolones, and most recently ketolides,
have been shown to be the most highly effective
antimicrobials against atypical pathogens, partic-
ularly Legionella. Because some of the atypical
pathogens are intracellular, e.g., Legionella, intra-
cellular antibiotic penetration into alveolar macr-
ophages (AM), is also important. Macrolides,
tetracyclines, quinolones and ketolides concen-
trate in AMs [12,16–19].
Atypical CAP pathogens are quantitatively
more important in the outpatient setting, and
qualitatively important in hospitalised patients
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with severe CAP. There are also public health
considerations that add to the importance of some
atypical CAP pathogens. Aside from the potential
role of C. pneumoniae in coronary artery disease
and multiple sclerosis, it is clear that C. pneumo-
niae and M. pneumoniae infection may be compli-
cated by asthma.M. pneumoniae and C. pneumoniae
infection are also important causes of nonexuda-
tive pharyngitis [21–28].
Zoonotic atypical pneumonias have always
been important causes of CAP in areas endemic
for these infectious diseases. Psittacosis remains
an important cause of CAP among those in
contact with psittacine birds. Q fever occurs
sporadically in those in close contact with par-
turient cats, or in sheep-raising areas. Endocardi-
tis is an infrequent but important problem in
endemic Q fever areas. Tularemia has six clinical
presentations, any of which may be accompanied
by pneumonia. In endemic areas tularaemia
remains an important and potentially serious
infectious disease [4,7,10,29–32].
Atypical pathogens are thus more important
than estimates of their relative incidence would
suggest in terms of diagnostic difﬁculties, nonb-
lactam susceptibility and their severity ⁄ complica-
tions.
CLINICAL DIAGNOSIS OF ATYPICAL
PNEUMONIAS
If a patient presents with pneumonia, and in
addition there are extrapulmonary ﬁndings, the
patient has an atypical pneumonia. Patients with
CAP plus extrapulmonary ﬁndings should, for
clinical purposes, be further subdivided into
those with zoonotic or nonzoonotic CAP. Zoonot-
ic atypical CAPs due to Q fever, psittacosis, or
tularaemia occur after contact with the respective
vectors. Psittacosis is an exception and may be
contracted after contact with well or ill psittacine
birds. Tularemia and Q fever CAP are not random
occurrences and a recent epidemiological contact
history is required before considering the diag-
nosis. If a patient with an atypical pneumonia has
a negative epidemiological contact history for
psittacosis, Q fever, or tularaemia, it is extremely
unlikely that the patient has a zoonotic atypical
CAP, [6,7,21–24] and it may be correctly assumed
that the patient has a nonzoonotic atypical
pneumonia due to Legionella, M. pneumoniae, or
C. pneumoniae (Table 1) [33–38].
CLINICAL DIFFERENTIATION OF
LEGIONELLA FROM OTHER TYPICAL
AND ATYPICAL CAPS
To differentiate Legionella from S. pneumoniae
CAP, cardiac, hepatic and renal abnormalities
are most reliable. CNS manifestations may occur
with S. pneumoniae CAP in patients who display
mental confusion secondary to fever or hypoxe-
mia. Patients with legionnaire’s disease will have
other non-CNS ﬁndings which will readily
permit clinical differentiation between these
two entities. The patient with S. pneumoniae and
mental confusion will have no other extrapul-
monary abnormalities, eliminating any potential
diagnostic confusion. CNS abnormalities clearly
illustrate the point that individual ﬁndings, e.g.,
mental confusion as an isolated clinical entity,
are not helpful in distinguishing between typical
and atypical pathogens. It is the pattern of
extrapulmonary abnormalities that provides the
basis for a syndromic diagnosis. The more
abnormalities that are present, the more statisti-
cally certain is the presumptive clinical diagnosis
[1,4,9–11,33–37].
Because each atypical pulmonary pathogen has
a different pattern of extrapulmonary organ
involvement, a presumptive clinical diagnosis
can be made if the characteristic pattern of organ
involvement is recognised by the clinician. It is
relatively straightforward to differentiate Legio-
nella from M. pneumoniae, but more difﬁcult to
differentiateM. pneumoniae from C. pneumoniae. In
practice, the main clinical problem is to differen-
tiate Legionella from S. pneumoniae and to differ-
entiate Legionella from M. pneumoniae CAP. Based
on the characteristic pattern of organ involve-
ment, Legionella patients invariably have several
of the following clinical or laboratory features:
CNS abnormalities (headache, mental confusion,
encephalopathy, lethargy); cardiac abnormalities
(relative bradycardia); gastrointestinal manifesta-
tions (watery diarrhoea, abdominal pain); hepatic
involvement (early or mild transient elevations of
the serum transaminases); renal abnormalities
(microscopic haematuria, increased creatinine);
muscle involvement (elevated CPK and aldolase),
and ⁄ or electrolyte abnormalities (hypophosphat-
aemia, hyponatraemia). In contrast, the pattern of
organ involvement characteristic ofM. pneumoniae
CAP excludes CNS involvement (except rarely
in patients with meningoencephalitis); includes
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upper respiratory tract involvement (otitis, bul-
lous myringitis, non-exudative pharyngitis); ex-
cludes cardiac involvement (no relative
bradycardia, rarely myocarditis); includes gastro-
intestinal involvement (watery diarrhoea but not
abdominal pain); excludes hepatic involvement;
excludes muscle involvement; includes skin
involvement (erythema multiforme); excludes
renal involvement (rarely glomerulonephritis);
and excludes electrolyte abnormalities. The dis-
tinctive laboratory feature of M. pneumoniae CAP
is a highly elevated cold agglutinin titre (‡ 1 : 64)
in 75% of patients. It should be apparent that
the most important characteristic features that
distinguish Legionella from M. pneumoniae CAP
are the presence of CNS, cardiac, hepatic, renal,
and electrolyte abnormalities in Legionella
infection, none of which are features of M. pneu-
moniae CAP [1,2,4–10,32–38].
Not every patient with Mycoplasma pneumonia
has an increase in cold agglutinins and those who
do have increases that are early or transient. Thus
the absence of increased cold agglutinins does
not rule out M. pneumoniae infection. Highly ele-
vated cold agglutinin titres (‡ 1 : 64) rule out non
M. pneumoniae etiologies [1,2,4–10,37,38] (Fig. 1).
CAP CO-INFECTIONS
Because co-infections, i.e., dual typical bacterial
pathogens, dual atypical pathogens, or typical
plus an atypical pathogen, are exceedingly rare
there is no need to expend diagnostic resources
looking for copathogens in patients with CAP.
Studies that have reported typical or atypical
copathogens have been based on culture for one
and serology for the other. Serological diagnoses,
particularly those based upon IgG titres, are
Table 1. Diagnostic features of the
non-zoonotic atypical pneumonias.
Adapted from Cunha, 2006 [6] Key Characteristics
Mycoplasma
pneumoniae
Legionnaire’s
disease
Chlamydophilia
(Chlamydia)
pneumoniae
Symptoms
Mental confusion ±a + –
Prominent headache – ± –
Meningismus – – –
Myalgias ± ± ±
Ear pain ± – ±
Pleuritic pain – ± –
Abdominal pain – + –
Diarrhoea + + –
Signs
Rash ±b – –
Non-exudative pharyngitis + – +
Haemoptysis – ± –
Lobar consolidation – ± –
Cardiac involvement ±c – –
Splenomegaly – – –
Relative bradycardia – + –
Shock ⁄ hypotensiong – + –
Chest X-ray
Inﬁltrates Patchy Rapidly progressive
Asymmetrical ±
consolidation
‘Circumscribed’
lesions
Bilateral hilar adenopathy – – –
Pleural effusion ± (small) ± ±
Laboratory Abnormalities
WBC count › ⁄ N › N
Hyponatraemia – + –
Hypophosphataemia – + –
Mild ⁄ early transient
increased AST ⁄ALT (SGOT ⁄ SGPT) – + –
› Cold agglutinins (‡ 1 : 64) + – –
Microscopic haematuria – ± –
Diagnostic Tests
Direct isolation (culture) +d +d +d
Serology CF IFA CF
Psittacosis CF litres – › ›
Legionella IFA litres – ››› –
Legionella DFA – +e –
Legionella urinary antigen – +f –
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CF, complement ﬁxation; DFA ⁄ IFA, direct ⁄ indi-
rect ﬂuorescent antibody test; N, normal; WBC, white blood cell; +, usually present; ±, sometimes present; –, usually
absent; ›, increased; ﬂ, decreased; ›››, markedly increased; ararely, only with Mycoplasma mengoencephalitis (cold
agglutinins > 1 : 512); berythema multiforme; cmyocarditis, heart block, or pericarditis; drequires special media;
erapidly becomes negative with anti-Legionalla therapy; fmay be falsely negative early, useful only Legionella
pneumophila (serotype 01); gwithout acute cardiac ⁄pulmonary events.
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problematic and are fraught with interpretational
difﬁculties. Increased M. pneumoniae or C. pneu-
moniae IgG titres in a patient with CAP indicate
past exposure and not active or concurrent infec-
tion. A patient with pneumococcal pneumonia
and elevated IgG titres to M. pneumoniae or
C. pneumoniae does not have co-pathogenicity
but rather serological evidence of preexposure in
a patient who actively has a single pathogen, i.e.,
S. pneumoniae [4–10,39–43].
CLINICAL DIAGNOSIS OF
LEGIONNAIRE’S DISEASE
Legionella, among the nonzoonotic atypical patho-
gens, is the one that is most likely to be misdiag-
nosed or present as severe CAP. The presumptive
diagnosis of legionnaire’s disease may be made
syndromically if the characteristic pattern of
organ involvement of legionnaire’s disease is
present. As with other infectious diseases, some
ﬁndings have greater diagnostic signiﬁcance than
others. The clinician should try to distinguish
between clinical ﬁndings that are compatible with
the diagnosis (nonspeciﬁc) and those that are
characteristic in combination (speciﬁc). Some
ﬁndings, such as mild transient elevations of the
serum transaminases, often go unnoticed, or their
diagnostic signiﬁcance is unappreciated in a
patient with CAP. Excluding noninfectious causes
of mild serum transaminase elevations, and if Q
fever and psittacosis can be eliminated on epide-
miological grounds, the only nonzoonotic atypical
CAP pathogen with mildly elevated transamin-
ases is legionnaire’s disease. Neither the diagnosis
nor the suspicion of the diagnosis is based upon
such a nonspeciﬁc ﬁnding alone. The mild eleva-
tions of the serum transaminases in a patient with
CAP are important in the context of accompany-
ing abnormalities, not because such elevations per
se are diagnostic. Similarly, an otherwise unex-
plained borderline low normal or decreased
serum phosphorous level in a patient with CAP
should suggest the possibility of legionnaire’s
disease. No other typical or atypical CAP is
associated with mild hypophosphataemia. Hypo-
natraemia, secondary to syndrome of inappropri-
ate ADH(SIADH), may occur because of a variety
of pulmonary disorders. Hyponatraemia is more
common and severe in legionnaire’s disease
compared with other CAPs, but hyponatraemia
is less diagnostically speciﬁc than hypophosphat-
aemia. Without an alternate explanation, micro-
scopic haematuria associated with CAP should
also suggest the possibility of legionnaire’s dis-
ease. Mild increases in serum creatinine which
may be elevated due to a variety of other
disorders, occur with Legionella. Microscopic hae-
maturia is relatively more important than mild
serum creatinine elevations in patients with poss-
ible Legionella CAP. Other laboratory tests that
suggest Legionella are a highly elevated C-reactive
protein (CRP) (‡ 30 units) in patients with CAP
and extrapulmonary ﬁndings. Erythrocyte sedi-
mentation rate (ESR) is elevated in Legionella but
is not helpful diagnostically compared with
highly elevated CRP levels. In legionnaire’s dis-
ease with muscle involvement or rhabdomyolysis,
serum aldolase and creatine phosphokinase
(CPK) levels may be elevated. No other CAP
with extrapulmonary manifestations is associated
with these ﬁndings. Patients with legionnaire’s
disease invariably have some, but not all, of the
aforementioned laboratory abnormalities, and the
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Fig. 1. Clinical diagnostic approach
to community-acquired pneumo-
nias. RB, relative bradycardia.
Adapted from Cunha BA [6,36,44].
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absence of any of them does not mean that the
patient does not have legionnaire’s disease. As
mentioned previously, a highly elevated cold
agglutinin titre (‡ 1 : 64) argues for the diagnosis
of M. pneumoniae and strongly against the diag-
nosis of Legionella or C. pneumoniae [1,2,4–10,39]
(Table 2).
WINTHROP-UNIVERSITY HOSPITAL
INFECTIOUS DISEASE DIVISION’S
WEIGHTED POINT SCORE SYSTEM
TO DIAGNOSE LEGIONNAIRE’S
DISEASE
Particularly with Legionella CAP, it is key to
distinguish extrapulmonary features compatible
with the diagnosis from those characteristic of the
diagnosis. Much of the problem in the literature is
centred on this point. The failure of some studies
to clinically differentiate legionnaire’s diease from
other typical or atypical pneumonias is based
either on a comparison of isolated clinical or
laboratory ﬁndings or an incorrect aggregation of
ﬁndings. For a syndromic diagnosis to be accu-
rate, it must be weighted, since characteristic
ﬁndings have more diagnostic importance than
those which are only consistent with the diagnosis
[37,38,44,45].
The single most important misunderstood and
misinterpreted clinical sign associated with
legionnaire’s disease is relative bradycardia. In
the literature, relative bradycardia, if described at
all as a ﬁnding in legionnaire’s disease, is never
deﬁned or is loosely described as a ‘pulse tem-
perature deﬁcit’. Relative bradycardia is a regular
feature of legionnaire’s disease and is a charac-
teristic sign and constant ﬁnding in legionnaire’s
disease irrespective of the Legionella species
[37,38,46].
If psittacosis and Q fever can be ruled out on
epidemiological grounds in patients with CAP,
relative bradycardia should suggest the possibil-
ity of legionnaire’s disease. Relative bradycardia
cannot be used as a diagnostic criterion in patients
with pacemaker-induced rhythms, arrhythmias,
or those on b-blocker medications. Temperature
increases the pulse by ten beats ⁄minute/F in
febrile states, and this relationship deﬁnes appro-
priate pulse ⁄ temperature relationships with any
given degree of fever > 102F. For example, in a
patient with a 103F temperature, the appropriate
pulse response is 120 beats ⁄minute. In this
patient, if relative bradycardia is present, the
pulse is £ 120 beats per minute and often in the
80–90 beats per minute range. Pulse/temperature
relationships are not altered by digitalis prepara-
tions, dihydropyridine calcium channel blockers,
or ACE inhibitors, but only by b-blockers or non-
dihydropyridine calcium channel blockers (dil-
tiazem, verapamil). Any patient on a b-blocker
who develops a fever will have relative brady-
cardia. For this reason, clinicians must be wary of
incorrectly ascribing relative bradycardia to
legionnaire’s disease in cardiac patients on b-
blockers and fever. Exclusions and criteria aside,
relative bradycardia is the most constant and
important physical sign in legionnaire’s disease.
Relative bradycardia may also be associated with
psittacosis or Q fever, but is not M. pneumoniae,
C. pneumoniae, or typical bacterial CAPs. A rapid
way to clinically differentiate M. pneumoniae from
Legionella CAP is by the presence or absence of
relative bradycardia. Relative bradycardia in a
patient with a zoonotic CAP should suggest Q
Table 2. Clinical features of legionnaire’s disease
Organ Common Features Uncommon Features Argues against involvement of legionnaire’s disease
Clinical features
CNS Headache, mental confusion, dullness, lethargy Dizziness Meningeal signs, seizures
HEENT None Vertigo Sore throat, ear pain, bullous myringitis, otitis media
Cardiac Relative bradycardia Legionella endocarditis Emboli to heart, joints, lungs, spleen, CNS
GI Loose stools, watery diarrhoea Abdominal pain Hepatic tenderness, peritoneal signs
Renal › Creatinine Acute renal failure CVA tenderness, chronic renal failure
Laboratory features
CSF Normal Mild pleocytosis RBCs, ﬂ glucose,› lactic acid
WBC count (blood) Leukocytosis Leukopenia thrombocytopeniaThrombocytosis,
Gram stain (sputum) No bacteria Few mononuclear cells, mixed ﬂora PMN predominance, predominant organismPurulent
sputum, single
Pleural ﬂuid Exudative pattern › WBCs RBCs,ﬂ pH, ﬂ glucose
SGOT ⁄ SGPT Mildly elevated (< 2 · normal) Moderately elevated (> 2 · normal) Markedly elevated (> 10 · normal)
Urine analysis Microscopic haematuria Proteinuria Myoglobulinuria Gross haematuria, pyuria, hemoglobinuria
CN, cranial nerve; CNS, central nervous system; CSF, cerebrospinal ﬂuid; CVA, costovertebral angle; GI, gastrointestinal; HEENT, head, eyes, ears, nose and throat; LUQ, left
upper quadrant; PVE, prosthetic valve endocarditis; RBC, red blood cell; RLQ, right lower quadrant; SBE, subacute bacterial endocarditis; WBC, white blood cell.
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fever or psittacosis but not tularemia. Relative
bradycardia strongly favours the diagnosis of
legionnaire’s disease and effectively rules out
M. pneumoniae and C. pneumoniae from further
diagnostic consideration (Table 3,4) [37,38,44].
Symptoms characteristic of legionnaire’s dis-
ease should be carefully looked for. In a patient
with CAP, the presence of otherwise unexplained
loose stools or diarrhoea limits diagnostic pos-
sibilities to M. pneumoniae and legionnaire’s
disease. Loose stools are more common than
diarrhoea, and diarrhoea is watery with Myco-
plasma and Legionella CAP. If a patient with CAP
has abdominal pain with or without loose stools
or diarrhoea, then Legionella is highly likely since
no other cause of CAP is associated with acute
abdominal pain [37,38].
Negative ﬁndings argue strongly for an alter-
nate diagnosis and are also helpful in ruling out
legionnaire’s disease. Upper respiratory tract
involvement is characteristic of M. pneumoniae
and Chlamydia pneumoniae CAP, but not of Legio-
nella CAP. The presence of ear signs, laryngitis, or
non-exudative pharyngitis in a patient with CAP
suggests M. pneumoniae or C. pneumoniae as the
most likely diagnostic possibilities, but also effect-
ively rules out legionnaire’s disease. Meningism
or seizures argue strongly against Legionella
infecion, but headache, mental confusion, ence-
phalopathy or lethargy are consistent with it.
Dermatological ﬁndings also effectively rule out
legionnaire’s disease from diagnostic considera-
tion in a patient with CAP. A maculopapular
facial rash (Horder’s spots) should suggest psit-
tacosis, a purple papule or extremity ulcer should
suggest tularaemia, and erythema multiforme
should suggest M. pneumoniae [1,2,4–10,37,38,44].
Combining positive and negative signs, symp-
toms, and laboratory features is the basis of a
syndromic diagnosis based upon a weighted point
system. The Winthrop-University Hospital point
system for diagnosing legionnaire’s disease has
very good sensitivity and speciﬁcity. To date, it
remains the best system for diagnosing legion-
naire’s disease. The weighted point system was
intended to give the clinician a probability index to
prompt speciﬁc testing for Legionella. The system
was intended to increase awareness of Legionella,
arrive at a presumptive clinical diagnosis, and
prompt speciﬁc testing for Legionella. It has
recently beenmodiﬁedwith even better sensitivity
and speciﬁcity than originally described in 1996.
The weighted point system has been in use by the
Infectious Disease Division at Winthrop-Univer-
sity Hospital for over a decade and the modiﬁed
version remains the best way to diagnose legion-
naire’s disease [15,46]. It is easily used and readily
available for clinicians to assess the probability of
legionnaire’s disease in patients with CAP. If the
system indicates high probability for Legionella,
anti-Legionella therapy should be included in the
empirical therapeutic regimen and speciﬁc tests for
Legionella should be ordered (Table 5) [20,47–49].
M. PNEUMONIAE AND
C. PNEUMONIAE CAP
M. pneumoniae and C. pneumoniae CAP closely
resemble each other in their clinical manifesta-
tions, but have some important distinguishing
features. Firstly, M. pneumoniae is an acute infec-
tious disease, while in contrast, C. pneumoniae
may be acute but is typically a chronic disease.
M. pneumoniae pneumonia, like other atypical
pneumonias, is characterised by its pattern of
extrapulmonary organ involvement [1,2]. Myco-
plasma has a predilection for the upper, as well as
Table 3. Causes of relative bradycardia. Adapted from
Cunha 2000, [46]
Infectious Causes Non-infectious Causes
Legionella b-blockers
diltiazem verapamil
Psittacosis CNS lesions
Q fever Lymphomas
Typhoid fever Factitious fever
Typhus Drug fever
Babesiosis
Malaria
Leptospirosis
Yellow fever
Dengue fever
Viral hemorrhagic fevers
Rocky Mountain spotted fever
Table 4. Determination of relative bradycardia. Repro-
duced with permission from Cunha, 2000 [46]
Inclusive criteria:
(1) Patient must be an adult (2) Temperature ‡ 102F (3) Pulse must be taken
simultaneously with the temperature elevation Exclusive criteria:
(1) Patient has no arrhythmias, 2nd ⁄ 3rd degree heart block, or a pacemaker-induced
rhythm (2) Patient must not be on b-blocker medications, diltiazem verapamil
Appropriate temperature-pulse relationships:
Temperature Beats ⁄min
41.1 C (106 F) 150
40.6 C (105 F) 140
40.7 C (104 F) 130
39.4 C (103 F) 120
38.9 C (102 F) 120
38.3 C (101 F) 110
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the lower, respiratory tract and thus patients with
CAP who have upper respiratory tract involve-
ment are most likely to have M. pneumoniae.
Common upper respiratory tract manifestations
of M. pneumoniae in a patient with CAP include
otitis, bullous myringitis, and mild nonexudative
pharyngitis. These ﬁndings are less frequent with
C. pneumoniae CAP. The most important clinical
ﬁnding to differentiate Mycoplasma from C. pneu-
moniae is the presence or absence of laryngitis.
Although all patients with C. pneumoniae CAP do
not have laryngitis, the majority of them do.
Patients presenting with a ‘mycoplasma-like ill-
ness’ with pneumonia-associated hoarseness
should be considered as having C. pneumoniae
until proven otherwise. Patients with CAP plus
upper respiratory tract involvement and highly
elevated cold agglutinin titres, i.e., ‡ 1 : 64, should
be considered as having M. pneumoniae CAP until
proven otherwise. Neither M. pneumoniae nor C.
pneumoniae infection is characterised by cardiac or
pulmonary involvement. Gastrointestinal
involvement is typical for Mycoplasma, and is
much less common with C. pneumoniae pneu-
monia. In a patient with CAP and otherwise
unexplained watery diarrhoea associated with
pneumonia, the differential diagnostic possi-
bilities are limited to Legionella and Mycoplasma
[4–10,50–58]. In patients with advanced cardio-
pulmonary disease and in compromised hosts,
M. pneumoniae or C. pneumoniae CAP may present
as severe CAP [59,60]. C. pneumoniae has been
associated with outbreaks in nursing home
aquired pneumonia (NHAP) [4,57,61].
LABORATORY DIAGNOSIS OF
ATYPICAL CAPS
Atypical pathogens are difﬁcult to culture or
dangerous to isolate. For this reason, clinical
syndromic diagnosis is essential to increase sus-
picion of the diagnosis and begin appropriate
empirical antimicrobial therapy as well as to
prompt speciﬁc diagnostic testing. Speciﬁc diag-
nostic testing is available for the atypical patho-
gens causing CAP. Legionella may be rapidly
diagnosed by direct ﬂuorescent antibody (DFA)
staining of sputum or respiratory secretions,
pleural ﬂuid, or lung specimens. DFA positivity
in sputum decreases rapidly after initiation of
Table 5. Modiﬁed Winthrop-Uni-
versity Hospital Infectious Disease
Division’s point system for diagno-
sing legionnaire’s disease in adults.
Adapted from Cunha, 2006 [6]
Qualifying conditions Point score
Clinical features
Temperature > 103Fa With relative bradycardia + 5
Headache Acute onset + 2
Mental confusion ⁄ lethargya Not drug-induced or metabolically ⁄
hypoxemia related
+ 4
Ear pain Acute onset ) 3
Nonexudative pharyngitis Acute onset ) 3
Hoarseness Acute not chronic ) 3
Sputum (purulent) Excluding chronic bronchitis ) 3
Haemoptysisa Mild ⁄moderate ) 3
Chest pain (pleuritic) acute onset ) 3
Loose stools ⁄watery diarrhoeaa Not drug induced + 3
Abdominal paina With ⁄without diarrhoea + 5
Renal failurea Acute not chronic + 3
Shock ⁄hypotensiona Not 2 to acute cardiac ) 5
⁄pulmonary causes + 5
Splenomegaly Excluding non-CAP causes ) 5
Lack of response to b-lactams After 72 h (excluding viral pneumonias) + 5
Laboratory Features
Chest X-ray Rapidly progressive asymmetrical inﬁltratesa + 3
(excluding severe inﬂuenza ⁄ SARS)
ﬂ PO2 with › A-a gradient (> 35)a (Excluding severe inﬂuenza ⁄ SARS) ) 5
ﬂ Na+ Acute onset + 1
ﬂ PO4a Acute onset + 5
› SGOT ⁄ SGPT (early mild ⁄ transient) Acute onset + 4
› Total bilirubin Otherwise unexplained + 1
› LDH (> 400)a Excluding HIV ⁄PCP ) 5
› CPK ⁄ aldolase Otherwise unexplained + 4
› CRP (> 30) Acute onset + 5
› Cold agglutinins (‡ 1 : 64) Acute onset ) 5
› Creatinine Acute onset + 2
Microscopic haematuriaa Excluding trauma, BPH, Foley
catheter, bladder ⁄ renal neoplasms + 2
Likelihood of Legionella (total points)
> 15 Legionella very likely
5–15 Legionella likely
< 5 Legionella unlikely
aOtherwise unexplained (acute and associated with pneumonia).
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anti-Legionella therapy. Indirect ﬂuorescent anti-
body testing (IFA) showing a single titre ‡ 1 : 512
is also diagnostic. Alternately, a four-fold or
greater rise in IFA IgG titres between acute and
convalescent specimens is also diagnostic of
legionnaire’s disease. The Legionella antigen test
has been useful in increasing Legionella awareness
and providing another diagnostic test for
L. pneumophila. If the Legionella antigen test is
positive, it is (diagnostic of) L. pneumophila (sero-
type 01), but a negative test does not rule out
legionnaire’s disease. The Legionella antigen test is
negative in non-L. pneumophila species and non-
serotype 01 whose frequency depends on geo-
graphic distribution. The main advantage of the
Legionella antigen test is that it remains positive
for weeks to months after the onset of antigenuria,
long after clinical resolution of the infection.
The main disadvantage of the Legionella antigen
test is that it is limited to one species, although
L. pneumophila (serotype 01) is the most common
Legionella species encountered. It takes several
days for antigenuria to develop in the course of
legionnaire’s disease. If the test is ordered too
early, it may be falsely negative as with early
serological tests. Legionella may also be cultured
on casitone-yeast extract (CYE) agar from sputum
or respiratory secretions [4–10].
M. pneumoniae and C. pneumoniae may be
cultured from respiratory secretions in special
viral media. More commonly, the diagnosis of
M. pneumoniae and C. pneumoniae is serological
[56]. An acutely elevated M. pneumoniae or
C. pneumoniae IgM titre in a patient with CAP is
diagnostic. A four-fold increase in IgGM. pneumo-
niae or C. pneumoniae titres is indicative of past
exposure or infection and is not diagnostic of
acute infection or concurrent infection [4–10,62].
Because C. psittaci is difﬁcult to isolate, diag-
nosis is entirely based on serological methods.
Elevated tube agglutination (TA) tests for
C. psittaci are diagnostic in nonimmune or
previously unexposed patients. The diagnosis of
tularemia and Q fever is also serological, since
these organisms are highly infectious, dangerous,
and difﬁcult to isolate. In nonimmune, nonex-
posed persons acute elevations of F. tularensis
IgM ⁄ IgG titres are diagnostic. Excluding high
initial acute titres for Q fever or tularemia, the
diagnosis of these zoonotic CAPs is based on a
four-fold increase in titres between acute and
convalescent specimens 4–8 weeks apart. Persist-
ently highly elevated C. burnetii IgG levels indi-
cate chronic Q fever infection rather than acute
infection 4–10,29–32].
Radiologically, viral pneumonias typically have
bilateral diffuse interstitial inﬁltrates without
pleural effusion (with the exception of adenoviral
pneumonia) or focal or segmental inﬁltrates plus
or minus pleural effusion. Atypical pneumonias
have no distinctive chest X-ray pattern. Pleural
effusions may be seen with tularemia and Legio-
nella and small effusions with M. pneumoniae.
There is no speciﬁc chest X-ray pattern for
Legionella, but rapidly progressive asymmetrical
inﬁltrates are typical [1,2,4–10,63–65].
ANTIMICROBIAL THERAPY FOR
ATYPICAL CAPS
Macrolides and Rifampin
During the initial outbreak of legionnaire’s dis-
ease in Philadelphia, it was realised that patients
did not respond to b-lactam therapy, but it soon
became apparent that antimicrobials that worked
intracellularly, i.e., macrolides and tetracyclines,
were effective. Erythromycin was usually effect-
ive, but therapeutic failures did occur. For this
reason, rifampin was added to increase anti-
Legionella activity. Doxycycline has more inherent
anti-Legionella activity than erythromycin or con-
ventional tetracyclines, and has been used as an
effective anti-Legionella agent for decades.
In addition to anti-Legionella activity, the other
therapeutic consideration in treating legionnaire’s
disease is intracellular penetration. Legionella is
an obligate intracellular organism and resides
in the alveolar macrophage (AM). The eradi-
cation of intracellular pathogens is ordinarily
difﬁcult because many antibiotics do not concen-
trate intracellularly. Fortunately, all agents active
against Legionella concentrate in the AM. The
efﬁcacy of erythromycin despite its limited anti-
Legionella potency may be explained because it
concentrates within the AM. Rifampin has anti-
Legionella activity in vitro, but clinical experience
with rifampin in combination therapy is limited.
Rifampin should not be used alone because of the
potential for the rapid development of resistance
to other organisms. With doxycycline and newer
more potent anti-Legionella agents, the rationale for
erythromycin plus rifampin combination therapy
has essentially been eliminated [5,15,61,62,66,67].
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Doxycycline
Doxycycline had a high degree of anti-Legionella
activity and is more active than either erythro-
mycin or tetracycline. If doxycycline is used to
treat moderate to severe legionnaire’s disease,
then a loading regimen, not a loading dose,
should be used to optimise the therapeutic
response. For moderate to severe Legionella CAP,
doxycycline should be administered at a dose of
200 mg (IV ⁄PO) every 12 h for 72 h, and then the
dose may be decreased to 100 mg (IV ⁄PO) every
12 h for the duration of therapy. Because doxy-
cycline displays concentration-dependent killing
kinetics at high dose, it may also be administered
as a single daily dose of 400 mg (IV ⁄PO) every
24 h as part of the 3-day loading regimen or as
200 mg (IV ⁄PO) for completion of therapy. To the
best of my knowledge, there has not been a
therapeutic failure using doxycycline when
administered with a loading regimen in treating
even severe Legionella CAP [4–6,68–76].
Respiratory Quinolones
The quinolones have revolutionised anti-Legionella
antimicrobial therapy. As good as doxycycline is,
the ﬂuoroquinolones are vastly superior in terms
of anti-in-vitro activity. Fluoroquinolones, like
other anti-Legionella antimicrobials, concentrate
in AM to achieve high intracellular concentrations.
Because of the potency of quinolones, particularly
the ‘respiratory quinolones’ against Legionella
species, there is no rationale for adding rifampin
or any other anti-Legionella drug to quinolone
therapy. There is sufﬁcient clinical experience to
conﬁrm the in-vivo efﬁcacy of the ﬂuoroquino-
lones in treating legionnaire’s disease. Because of
the importance of atypical organisms in CAP
(15%), and in particular because of the potential
for severe CAP with Legionella, the preferred
empirical monotherapy for moderate ⁄ severe CAP
is a ‘respiratory ﬂuoroquinolone’. ‘Respiratory
quinolones’ are highly active against the typical
pathogens causing CAP, and are highly active
against all of the zoonotic and nonzoonotic path-
ogens as well. Empirical ‘respiratory quinolone’
monotherapy offers many advantages including
the simplicity, cost savings, pharmacokinetics
and minimal drug reactions and as well as pro-
viding optimal coverage for typical and atypical
pathogens using a single antimicrobial.
‘Respiratory quinolones’ have excellent bio-
availability and lend themselves readily to intra-
venous/oral switch programmes. Patients
receiving ‘respiratory quinolone’ oral therapy
have the same blood and lung levels as those
receiving the same dose intravenously. Critically
ill patients may be started on intravenous therapy
and should be switched to the oral equivalent as
soon as the patient responds, if oral therapy can
be given. With erythromycin and tetracycline,
therapy for legionnaire’s disease continued for
4–6 weeks to prevent relapse. Although clinical
experience is limited, it appears that 2 weeks of
therapy with highly active, anti-Legionella antibi-
otics, e.g., ‘respiratory quinolones’, appear to
provide adequate therapy [77–82].
Telithromycin
Ketolides also have a high degree of anti-Legio-
nella activity. Telithromycin is a ketolide that is
available at the present time only as an oral
formulation. Telithromycin is useful therefore as
monotherapy for the empirical treatment of mild
to moderate typical ⁄ atypical CAP when oral
therapy is desired. Telithromycin also may be
used in switch therapy when therapy has been
initiated with an intravenous anti-Legionella
agent [83–85].
SEVERE CAP DUE TO ATYPICAL
PATHOGENS
The severity of CAP is related primarily to the
underlying immune status and cardiopulmonary
function of the host. For this reason, pathogens of
relatively low virulence, e.g., M. pneumoniae, in a
patient with advanced lung disease can present as
severe CAP. Of the atypical pathogens, Legionella
is most likely to present as severe CAP requiring
hospitalisation and ICU admission. Therapy of
severe CAP is usually initiated intravenously, and
after clinical defervescence, therapy may be
switched to an oral equivalent [86–93].
IMPORTANCE OF M. PNEUMONIAE
AND C. PNEUMONIAE
C. pneumoniae CAP closely resembles M. pneumo-
niae CAP. The epidemiology of C. pneumoniae also
parallels that of M. pneumoniae except in NHAP.
C. pneumoniae has been shown to cause outbreaks
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in patients in chronic care facilities and this has
not been the case with M. pneumoniae. Both
M. pneumoniae and C. pneumoniae CAP are most
common in the ambulatory setting in young
adults, but are responsible for a small number
of patients who are hospitalised with CAP.
M. pneumoniae and C. pneumoniae may present in
patients with severely compromised respiratory
function as severe CAP. M. pneumoniae, and to a
lesser extent C. pneumoniae, may precipitate an
attack of asthma or exacerbate existing asthma.
Some patients who have recently had M. pneumo-
niae CAP develop post-CAP asthma which may
be permanent. It would seem that M. pneumoniae
which resides on the surface of the respiratory
epithelium is in a perfect position to cause
bronchial or hyper-reactivities and ⁄ or broncho-
spasm. The treatment of M. pneumoniae and
C. pneumoniae CAP is important, not because of
the severity of the illness, but if for no other
reason, to decrease communicability and to
decrease post-CAP asthma [4–10,94,95].
C. pneumoniae has important public health
implications in addition to CAP. C. pneumoniae
chronic infection has been implicated in the
aetiology of MS and coronary artery disease.
Researchers at Vanderbilt University School of
Medicine have used PCR and sophisticated diag-
nostic techniques to diagnose Chlamydia pneumo-
niae in patients with MS. They have achieved very
good results, even in patients with far advanced
MS, using prolonged anti-C. pneumoniae treat-
ment. The role of C. pneumoniae in coronary artery
disease remains controversial. Some trials have
been conducted to evaluate the prophylactic
value of antichlamydial prophylaxis in the pre-
vention of CAD, but these studies have been
inconclusive. Future studies will determine the
role of C. pneumoniae in CAP and MS as well as
other chronic infectious diseases [80,96–100].
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